AlphAIalphai — Financial news for AI agents
manilatimes.netJUN 97 min read$SUJABullishMed

Suja Life Reports First Quarter 2026 Financial Results

Suja Life (NASDAQ: SUJA) reported first-quarter 2026 net sales of $107.1 million, up 22.5% year over year from $87.4 million. Adjusted EBITDA rose 66.3% to $25.0 million, with margin expanding to 23.4%. Net income was $7.7 million versus a prior-year net loss. The company initiated 2026 guidance: net sales $367–$371 million and Adjusted EBITDA $70–$72 million.

AI DeskJune 9, 2026
Source · manilatimes.net
AI analysis
Relevance
9/10
Novelty
9/10
Actionability
Med
Sentiment · $SUJA
Bullish
Timing
today’s Q1 results and same-day FY2026 outlook
Market alignment
supports a growth-and-margin narrative consistent with positive early trading for newly public consumer brands
Why this matters for $SUJA

Q1 shows strong top-line and profitability expansion, and FY2026 guidance implies continued growth and margin/EBITDA scaling.

Relevance context

Suja Life reports Q1 2026 results and initiates FY2026 outlook, including net sales, Adjusted EBITDA, and full-year guidance.

Price-impact prediction

Likely positive near-term bias as guidance provides a fresh valuation anchor for a newly public name.

Background

Suja Life began trading on Nasdaq under SUJA on May 7, 2026 and completed its IPO on May 8, 2026; this is its first-quarter post-IPO financial update with an FY2026 outlook.

Why it matters

The print highlights accelerating net sales (+22.5% YoY) and a sharp jump in Adjusted EBITDA (+66.3% YoY), alongside gross margin expansion and a shift to positive net income. The FY2026 guidance provides a concrete growth and profitability roadmap (net sales $367–$371M; Adjusted EBITDA $70–$72M).

Market relevance

Traders can update forward models using the explicit FY2026 ranges and assess whether Q1 margin expansion and EBITDA leverage are sustainable.

Market effects

Sector

Reinforces demand/read-through for “better-for-you” natural beverage brands with functional benefits and clean ingredients.

Regional

No specific regional spillover beyond US retail distribution performance.

Global

Limited; primarily US consumer packaged beverages and domestic distribution.

Alternative perspectives

Contrarian view

Adjusted EBITDA outperformance may be sensitive to promotional intensity, freight costs, and shipment timing rather than durable underlying demand.

Overlooked factors

SG&A as a % of sales rose (35.3% vs 41.3% prior year, but freight increased), and the company notes inability to reconcile forward Adjusted EBITDA to GAAP net income, leaving GAAP earnings visibility limited.

Key entities

  • public_company
    Suja Life, Inc.

    Reports Q1 2026 financial results and initiates FY2026 outlook; newly public on Nasdaq (SUJA).

  • executive
    Maria Stipp

    CEO quoted on Q1 performance drivers and growth positioning.

Read at source← All news

Related articles

JUN 3
$SUJAMed

Suja Life (NASDAQ:SUJA) Upgraded to “Strong-Buy” at Evercore

Evercore upgraded Suja Life (NASDAQ:SUJA) to a “strong-buy” rating in a Monday research note, according to Zacks.com. Other firms also initiated coverage: Goldman Sachs set a $31 target and a “buy,” Jefferies set a $25 target and a “buy,” and William Blair rated “outperform.” MarketBeat data show a consensus “Buy” and average target $26.67.

themarketsdaily.com2 min
JUN 1
$NVDAMed

Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Broadcom, Microsoft, IBM, Meta, Tyson Foods & more

Wall Street analysts issued multiple calls Monday. Goldman initiated HawkEye 360 as buy; Morgan Stanley upgraded Dell to equal weight; Wells Fargo upgraded Tandem Diabetes Care to overweight. Citizens initiated Microsoft at Market Outperform with a $550 target; Barclays initiated IBM at overweight with a $350 target. Cantor reiterated Tesla overweight; RBC reiterated Meta outperform. Broadcom was reiterated overweight by Morgan Stanley, raising its target to $485.

cnbc.com6 min
JUL 11
$AZNHighAI 8/10

AstraZeneca Plunges After New Heart Disease Drug Fails Trial

AstraZeneca said its heart disease drug Wainua failed to beat placebo in a clinical trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), according to AstraZeneca and Ionis Pharmaceuticals. AstraZeneca shares fell up to 10.6% in London and 5.7% on the NYSE. Rival ATTR-CM drug makers Pfizer, BridgeBio, and Alnylam initially moved higher or lower.

yahoo.com3 min
JUL 11
$WDFCMedAI 8/10

WD-40 Q3 Earnings Call Highlights

WD-40 Company (NASDAQ:WDFC) reported Q3 gross margin of 56.6% and non-GAAP net income of $31.5 million, with non-GAAP EPS of $2.33. EMEA sales rose 17% to $66.6 million and Asia-Pacific sales rose 24% to $27.3 million. FY2026 constant-currency net sales guidance is $652 million to $667 million. The board authorized a $100 million share repurchase program.

yahoo.com4 min
JUL 11
$RXSTMedAI 8/10

RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook

RxSight (NASDAQ:RXST) reported Q2 sales of 11 Light Delivery Devices (LDDs) and one LDD rental, lowering sales 20% and leaving an installed base of 1,166 units. Cash, cash equivalents and short-term investments were about $209M. It revised 2026 revenue to $140M-$160M, including $110M-$120M RxSight sales and $30M-$40M Alcon collaboration revenue, and raised gross margin outlook to 73%-75%.

yahoo.com4 min
JUL 11
$WDFCHighAI 9/10

Why WD-40 Stock Popped Today

WD-40 (WDFC) shares rose after the company reported fiscal 2026 Q3 net sales up 24% to $195 million and adjusted EPS of $2.33, above the $1.56 estimate. Operating income increased 47% to $40.3 million. WD-40 raised full-year guidance to net sales of $675-$690 million and adjusted EPS of $6.05-$6.35.

yahoo.com4 min